S-1/A: Bio-Path Holdings Files Amendment No. 1 to Form S-1 Registration Statement

Sentiment:

S-1/A Filing 13 March 2024 8:33 AM

Bio-Path Holdings files an amendment to its Form S-1 registration statement primarily to include an exhibit related to legal opinion on the securities being registered.

Capital raiseThe registration statement relates to the proposed offer and sale by the Company of up to: (i) 1,152,073 shares (the Shares) of the Company's common stock, par value $0.001 per share (Common Stock); (ii) pre-funded warrants to purchase up to 1,152,073 shares of Common Stock (the Pre-Funded Warrants); (iii) the shares of Common Stock issuable upon the exercise of the Pre-Funded Warrants (the Pre-Funded Warrant Shares); (iv) warrants to purchase up to 2,304,146 shares of Common Stock (the Common Warrants and together with the Pre-Funded Warrants, the Warrants); and (v) the shares of Common Stock issuable upon the exercise of the Common Warrants (the Common Warrant Shares and together with the Pre-Funded Warrant Shares, the Warrant Shares).

Summary

Bio-Path Holdings, Inc. filed Amendment No. 1 to its Form S-1 registration statement on March 13, 2024.
The amendment is primarily for the purpose of filing Exhibit 5.1, which is a legal opinion from Winstead PC.
The registration statement relates to the proposed offer and sale of common stock, pre-funded warrants, and common warrants.
The estimated expenses for the issuance and distribution of securities, excluding placement agent fees, total $111,821.
This includes SEC registration fees, FINRA filing fees, legal fees, and other expenses.

Sentiment

Score: 6

Explanation: The document is a regulatory filing, so the sentiment is neutral. It's a necessary step for the company to potentially raise capital, but doesn't inherently indicate positive or negative performance.

Positives

The legal opinion from Winstead PC supports the validity of the shares and warrants being offered.
The company has taken steps to ensure indemnification of its directors and officers, which is a standard corporate governance practice.

Risks

The enforceability of the warrants may be limited by bankruptcy, insolvency, or other laws affecting creditors' rights.
Indemnification for liabilities arising under the Securities Act may be unenforceable according to the SEC's opinion.

Future Outlook

The registration statement indicates the company intends to offer and sell securities, but does not provide specific forward-looking statements beyond that.

Industry Context

This filing is a standard step for a company seeking to raise capital through the issuance of securities. The legal opinion and other exhibits are required for regulatory compliance.

Comparison to Industry Standards

The expenses listed for the offering, such as legal and accounting fees, are typical for similar-sized companies undertaking a securities offering.
Indemnification agreements for directors and officers are standard practice in corporate governance, aligning with industry norms.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Indemnification	The company's certificate of incorporation and bylaws provide for indemnification of directors and officers to the fullest extent permitted by applicable law.	N/A	This protects the company's directors and officers from certain liabilities, encouraging them to take appropriate risks for the benefit of the company.

Stakeholder Impact

Shareholders may be affected by the potential dilution from the issuance of new shares.
The capital raise could provide the company with additional resources to fund its operations and research, potentially benefiting stakeholders in the long term.

Next Steps

The company will need the SEC to declare the registration statement effective.
Following effectiveness, the company can proceed with the offering and sale of the securities.

Key Dates

Date	Description
September 27, 2007	Agreement and Plan of Merger and Reorganization dated September 27, 2007, by and among the Company, Biopath Acquisition Corp., a Utah corporation and wholly owned subsidiary of the registrant, and Bio-Path, Inc., a Utah corporation
January 6, 2015	Certificate of Incorporation
March 16, 2015	Form of Common Stock Certificate
June 24, 2015	Controlled Equity OfferingSM Sales Agreement, dated June 24, 2015, by and between the Company and Cantor Fitzgerald & Co.
February 9, 2018	Certificate of Amendment to the Certificate of Incorporation of Bio-Path Holdings, Inc.
April 2, 2018	Form of Warrant issued to Roth Capital Partners, LLC
January 16, 2019	Certificate of Amendment to the Certificate of Incorporation of Bio-Path Holdings, Inc.
March 5, 2020	Subsidiaries of Bio-Path Holdings, Inc.
May 16, 2022	Second Amendment to Bio-Path Holdings, Inc. 2017 Stock Incentive Plan
November 9, 2022	Completion of a registered direct offering with certain institutional and accredited investors for the sale of an aggregate of 40,000 shares of our common stock for gross proceeds of approximately $2.0 million.
March 8, 2024	Initial filing date of the Registration Statement on Form S-1 (File No. 333-277802).
March 13, 2024	Filing date of Amendment No. 1 to the Registration Statement on Form S-1.

Keywords

registration statement, securities, warrants, common stock, Bio-Path Holdings, offering

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.